Fourth-generation fluoroquinolones in tuberculosis

The Lancet

Volumn 373, Issue 9670, 2009, Pages 1148-1149

  Rieder, Hans L ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; MOXIFLOXACIN; NALIDIXIC ACID; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM CULTURE; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS;

EID: 63549142301     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60559-6     Document Type: Note

References (14)

1. Comroe Jr. J.H. Pay dirt: the story of streptomycin. Part I: from Waksman to Waksman. Am Rev Respir Dis 117 (1978) 773-781
2. Lehmann J. Twenty years afterward: historical notes on the discovery of the antituberculosis effect of para-aminosalicylic acid (PAS) and the first clinical trials. Am Rev Respir Dis 90 (1964) 953-966
3. Meyer H., and Mally J. On hydrazine derivatives and pyridine carbonic acids. Monatshefte Chemie verwandte Teile anderer Wissenschaften 23 (1912) 393-414 (in German).
4. Sensi P., Margalith P., and Timbal M.T. Rifomycin, a new antibiotic-preliminary report. Farmaco Ed Sci 14 (1959) 146-147
5. Brouet G., and Roussel G. Trial 6.9.12. Overall methodology and summary of results. Rev Fr Mal Respir 5 suppl 1 (1977) 5-13 (in French).
6. Lesher G.Y., Froelich E.J., Gruett M.D., Bailey J.H., and Brundage R.P. 1,8-naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 5 (1962) 1063-1065
7. Conde M.B., Efron A., Loredo C., et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373 (2009) 1183-1189
8. Mitchison D.A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 147 (1993) 1062-1063
9. Dobler C.C., Crawford A., Jeffs P.J., Gilbert G.L., and Marks G.B. Recurrence of tuberculosis in a low-incidence setting. Eur Respir J 33 (2009) 160-167
10. Crofton J. "Sputum conversion" and the metabolism of isoniazid. Am Rev Tuberc Pulm Dis 77 (1958) 869-871
11. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis (2006), World Health Organization, Geneva. http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf WHO/HTM/TB/2006. (accessed March 30, 2009).
12. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008 (Sept 25, 2008). http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf (accessed March 17, 2009).
13. Nathanson E., Gupta R., Huamani P., et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8 (2004) 1382-1384
14. Keshavjee S., Gelmanova I.Y., Farmer P.E., et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372 (2008) 1403-1409